Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).
The new structures are being developed by scientists from the University of Bristol, using proteins from alpha helices - one of the fundamental ways that strings of amino acids fold - to create long fibres called hydrogelating self assembling fibres (hSAFs), or hydrogels. By learning how to build hSAFs from scratch, the researchers are starting to understand how they might use these 3D scaffolds to support the growth of nerves, blood vessels and cartilage tailored to the needs of individual patients.
Professor Dek Woolfson who is leading the work, explains: "To make hydrogels you need something long and thin that will interact with copies of itself and form meshes, but is also water soluble. However rather than using natural proteins, which are complex, we've tried to make something as simple as possible that we fully understand using peptides and self assembling proteins."
Currently, hydrogel scaffold structures, made either synthetically or from natural resources such as seaweed, are used in everyday products from shampoos to drug capsules.
But explains, Professor Woolfson, the hSAFs his team are developing will have different uses: "The downside of using peptides or proteins is that they are expensive compared with synthetic polymers. We are almost certainly looking at high end biomedical applications, generating cells which can be used in living systems. Potential medical benefits include growing tissues such as skin, nerves and cartilage in the laboratory which will advance basic research and may lead to biomedical applications like speeding up wound healing and grafting."
Commenting on the research, BBSRC Chief Executive Professor Doug Kell, said: "This research highlights the importance of understanding how things work at a micro level and then looking at different ways to apply this knowledge to create effective solutions for tackling everyday problems, in this instance, translating basic bioscience into technology which could have very real clinical benefits for patients."
This research is featured in the latest edition of Business, the quarterly magazine of BBSRC.
BBSRC Media Office
Tracey Jewitt, Tel: 01793 414694, email: firstname.lastname@example.org
Nancy Mendoza, Tel: 01793 413355, email: email@example.com
Matt Goode, Tel: 01793 413299, email: firstname.lastname@example.org
NOTES TO EDITORS
This research features in the Autumn 2009 issue of Business, BBSRC's research highlights magazine.
To read the full article, visit: http://www.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £450 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors. BBSRC carries out its mission by funding internationally competitive research, providing training in the biosciences, fostering opportunities for knowledge transfer and innovation and promoting interaction with the public and other stakeholders on issues of scientific interest in universities, centres and institutes.
The Babraham Institute, Institute for Animal Health, Institute of Food Research, John Innes Centre and Rothamsted Research are Institutes of BBSRC. The Institutes conduct long-term, mission-oriented research using specialist facilities. They have strong interactions with industry, Government departments and other end-users of their research.
For more information see: http://www.